Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab...

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Rituximab, a CD20-targeting monoclonal antibody, is used for rheumatoid arthritis.
• Peripheral blood CD4+ T-cell depletion is noted after initial rituximab cycles.
• Non-responders to rituximab show an absence of CD4+ T-cell decrease.

Purpose of the Study:

• To investigate CD4+ T-cell changes during repeated rituximab cycles.
• To correlate CD4+ T-cell dynamics with clinical outcomes in rheumatoid arthritis patients.

Main Methods:

• Analysis of rheumatoid arthritis patients receiving rituximab (July 2007-July 2013).
• Lymphocyte phenotyping and clinical assessments pre- and post-rituximab cycles (3 and 6 months).
• Comparison of lymphocyte counts and disease activity using nonparametric tests.

Main Results:

• Patients received up to seven rituximab cycles.
• Mean CD4+ T-cell counts remained above the reference range before infusions.
• CD4+ T-cell counts returned to the reference range by 3-6 months post-infusion and decreased with disease activity.

Conclusions:

• CD4+ T-cell counts may serve as a biomarker for rituximab response in rheumatoid arthritis.
• Monitoring CD4+ T-cell levels can inform retreatment decisions.
• CD4+ T-cell dynamics correlate with disease activity in rheumatoid arthritis patients treated with rituximab.